{"id":"W4387812349","doi":"10.1016/j.annonc.2023.09.1394","title":"101P Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Zymeworks (Canada)","funders":"Pharmacyclics; Genentech; European Society for Medical Oncology; Centre for Mathematical Cognition, Loughborough University; Ipsen; Sociedad Española de Oncología Médica; BeiGene; Loxo Oncology; Astellas Pharma; Novocure; Eisai; Jazz Pharmaceuticals; Incyte; F. Hoffmann-La Roche; FibroGen; Celgene; Bristol-Myers Squibb; American Society of Clinical Oncology; Amgen; Pfizer; Agios Pharmaceuticals","keywords":"Medicine; Biliary tract cancer; Internal medicine; Quality of life (healthcare); Biliary tract; Gastroenterology; Oncology; Cancer; Gemcitabine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007495633,0.0002634055,0.0005223438,0.0002896802,0.0002537675,0.0006977657,0.0002200367,0.0002862501,0.001703865],"category_scores_gemma":[0.001240154,0.0002020088,0.001491591,0.0007815091,0.0001437179,0.0003454613,0.0003543394,0.0007794541,0.0001526514],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005865828,"about_ca_system_score_gemma":0.0003796438,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004082368,"about_ca_topic_score_gemma":0.007542521,"domain_scores_codex":[0.9996474,0.0001570814,0.00003985091,0.00003908482,0.00004315713,0.00007355586],"domain_scores_gemma":[0.9996088,0.00006835983,0.0001988283,0.00002113706,0.00003232371,0.00007059635],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.06179767,0.001095342,0.8804208,0.0009344518,0.007828581,0.0001788138,0.0001899187,0.001041254,0.001895503,0.0003016291,0.003402584,0.04091335],"study_design_scores_gemma":[0.005310976,0.006470902,0.9820222,0.00009374944,0.002708901,0.0001682253,0.0001780392,0.0003816205,0.000280881,0.0001436096,0.002220099,0.00002087383],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915928,0.003272758,0.00008046398,0.0002054729,0.00003728621,0.00007285916,0.003172574,0.00000334531,0.001562458],"genre_scores_gemma":[0.9944403,0.001036072,0.0001064607,0.0001544206,0.00002035447,0.00008438818,0.003511183,0.000001786959,0.0006450025],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004082368,"threshold_uncertainty_score":0.008117259,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1182395071198482,"score_gpt":0.436515297590777,"score_spread":0.3182757904709288,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}